Grail has sold 180,000 of its cancer tests, but needs FDA approval to scale up its business (Credit: Grail)

Grail pi­o­neered mul­ti-can­cer tests. But the com­pa­ny’s rough pub­lic de­but shows the in­dus­try could be in trou­ble

Is Grail’s lurch­ing start as a new­ly pub­lic com­pa­ny a bad omen for what some view as the fu­ture of can­cer test­ing?

In its first …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.